Adversarial Injection · Teclistamab (Tecvayli; JNJ-64007957; CAS 2187990-05-0; MW ~148,000 Da; IgG4 kappa bispecific antibody [DuoBody technology; anti-BCMA (TNFRSF17; CD269) × anti-CD3ε]; [SIXTY-SIXTH MECHANISM CLASS in Glyphward 639-attack portfolio — FIRST BCMA (B-CELL MATURATION ANTIGEN; TNFRSF17; CD269) × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761291 OCTOBER 25 2022) — DISTINCT FROM BELANTAMAB MAFODOTIN (BCMA ADC; attack #634; first BCMA-targeting therapy ever any modality) — TECLISTAMAB IS FIRST BCMA-TARGETED T-CELL REDIRECTING THERAPY EVER: DuoBODY TECHNOLOGY (GENMAB; controlled Fab-arm exchange: two IgG4 parent antibodies each with complementary Fc mutations [Phe405Leu + Lys409Arg] incubated under mild reducing conditions → controlled Fab-arm exchange in vitro → asymmetric bispecific IgG4 with one anti-BCMA Fab-arm + one anti-CD3ε Fab-arm; IgG4 backbone: no ADCC/CDC [Ser228Pro hinge stabilization against Fab-arm exchange in vivo]); BCMA TARGET BIOLOGY: BCMA (B-Cell Maturation Antigen; TNFRSF17; CD269; TNFRSF13A; gene 16p13.1; MW ~20 kDa type III transmembrane protein; 184 aa; 1 extracellular cysteine-rich domain [CRD]); BCMA survival signals: BAFF (BLyS) + APRIL bind BCMA → NF-κB activation → anti-apoptotic Bcl-2/Bcl-xL → plasma cell survival; BCMA expression: HIGH on normal plasma cells (late B-cell differentiation); ALL multiple myeloma plasma cells (>90% expression); not expressed on naive/memory B cells → selective against terminally differentiated plasma cells; soluble BCMA (sBCMA): cleaved by ADAM10/17 → decoy receptor in blood (serum sBCMA level correlates with tumor burden in myeloma); teclistamab mechanism: BCMA Fab-arm binds BCMA on myeloma cell surface → CD3ε Fab-arm simultaneously engages CD3ε on cytotoxic T lymphocyte → ternary immunological synapse → T-cell activation → perforin/granzyme B → myeloma cell lysis (polyclonal; MHC-independent; independent of myeloma cell BCR or TCR specificity); SUBCUTANEOUS FORMULATION: first SC bispecific T-cell engager for hematologic malignancy; SC injection (vs blinatumomab 28-day continuous IV CADD pump [attack #630]); step-up dosing to manage CRS: 0.06 mg/kg SC (Week 1 day 1) → 0.3 mg/kg SC (Week 1 day 4) → 1.5 mg/kg SC QW (maintenance weeks 2+) → after ≥6 months sustained response: 1.5 mg/kg SC Q2W; MajesTEC-1 PHASE 2 (NCT04557098): n=165 R/R MM ≥4 prior lines (including proteasome inhibitor, immunomodulatory drug [IMiD], anti-CD38 antibody); ORR 63.0% (104/165); VGPR+ 58.5%; CR 39.4%; sCR 28.3%; DOR median ≥22 months (not reached); CRS 72.1% (Grade 1-2; Grade 3 3.0%); ICANS 14.5% (Grade 3 3.0%); NONE OF THESE — BCMA×CD3 bispecific mechanism, DuoBody Fab-arm exchange technology, Phe405Leu Lys409Arg mutations, SC Q2W dosing, MajesTEC-1 ORR 63% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2187990-05-0]) · First BCMA×CD3 Bispecific T-Cell Engager + DuoBody IgG4 + SC Q2W + MajesTEC-1 ORR 63% · Attack #639

Teclistamab (Tecvayli; JNJ-64007957; CAS 2187990-05-0; MW ~148,000 Da; [SIXTY-SIXTH MECHANISM CLASS — FIRST BCMA (B-CELL MATURATION ANTIGEN; TNFRSF17; CD269) × CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761291 OCTOBER 25 2022); DuoBODY TECHNOLOGY (GENMAB CONTROLLED Fab-ARM EXCHANGE Phe405Leu + Lys409Arg IgG4 BISPECIFIC); FIRST SUBCUTANEOUS BISPECIFIC T-CELL ENGAGER FOR MULTIPLE MYELOMA (STEP-UP SC Q1W → Q2W; DISTINCT FROM BLINATUMOMAB 28-DAY CONTINUOUS IV CADD PUMP); MajesTEC-1 ORR 63.0% VGPR+ 58.5% CR 39.4% (R/R MM ≥4 PRIOR LINES); JANSSEN BIOTECH; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Janssen Biotech Horsham PA (BLA 761291 US holder; Tecvayli US commercialization; 0.00046 µg/m³ → displayed ÷10), Janssen Biologics BV Leiden Netherlands (Tecvayli global manufacturing; DuoBody bispecific production; 0.00029 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (MajesTEC-1 enrollment; myeloma pharmacist; 0.00017 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + BCMA×CD3 Bispecific Absent + DuoBody Fab-Arm Exchange Absent + SC Q2W Absent + MajesTEC-1 ORR 63% Absent: AI Prompt Injection via EHS Monitor Report AI

Teclistamab (CAS 2187990-05-0; NIOSH HD Category 1) is the sixty-sixth mechanism class in the Glyphward adversarial portfolio — the first BCMA (B-Cell Maturation Antigen; TNFRSF17; CD269) × CD3 bispecific T-cell engager ever FDA approved (BLA 761291 October 25 2022). Teclistamab employs DuoBody IgG4 bispecific technology (Genmab; controlled Fab-arm exchange via Phe405Leu + Lys409Arg mutations), enabling subcutaneous SC Q2W maintenance dosing. MajesTEC-1 achieved ORR 63.0%, CR 39.4% in R/R multiple myeloma after ≥4 prior lines. None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 2187990-05-0.

Teclistamab as Sixty-Sixth Mechanism Class: First BCMA×CD3 Bispecific T-Cell Engager

Teclistamab (CAS 2187990-05-0) represents the sixty-sixth mechanism class in the Glyphward portfolio: the first BCMA (B-Cell Maturation Antigen; TNFRSF17; CD269) × CD3 bispecific T-cell engager ever FDA approved in any indication (BLA 761291 October 25 2022 accelerated approval for R/R multiple myeloma after ≥4 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody). Teclistamab is distinct from belantamab mafodotin (Blenrep; class #61; first BCMA-targeting therapy ever any modality) which is a BCMA-targeted antibody-drug conjugate (ADC) with MMAF cytotoxic payload — teclistamab is the first BCMA-directed T-cell engager (bispecific antibody recruiting polyclonal T cells). DuoBODY BISPECIFIC TECHNOLOGY (Genmab AS, Copenhagen Denmark): conventional IgG1/IgG4 monospecific antibodies are homodimers (two identical Fab arms + one Fc); generation of bispecific antibodies with one Fab arm from antibody A and one from antibody B requires preventing homodimerization; Genmab's DuoBody approach: each parental IgG4 antibody carries a single CH3 domain point mutation (parental A: Phe405Leu; parental B: Lys409Arg) that reduces Fc homodimerization stability; when the two parental IgGs are mixed under mild reducing conditions (pH 7.4; 2-MEA reducing agent; 31°C; 5 hours) → intrachain disulfides in the hinge region are reduced → Fab-arm exchange → statistical reassortment produces homodimer A (A-A), homodimer B (B-B), and heterodimer A-B in ~25%:25%:50% ratio → controlled Fab-arm exchange (CFE); purification (protein A chromatography; ion exchange) → near-pure heterodimer bispecific IgG4; ANTI-BCMA Fab ARM: binds BCMA (TNFRSF17; CD269; B-Cell Maturation Antigen; gene 16p13.1; 184 aa; type III transmembrane protein; single extracellular cysteine-rich domain CRD); BCMA is highly expressed on normal plasma cells and on essentially all multiple myeloma (MM) plasma cells; BCMA is minimally expressed on naive B cells, T cells, NK cells (myeloma selectivity); BCMA signaling: APRIL (a proliferation-inducing ligand) + BAFF bind BCMA → TRAF3/TRAF6 → NF-κB → anti-apoptotic proteins (Bcl-2; Bcl-xL; Mcl-1) → plasma cell survival; soluble BCMA (sBCMA; shed by ADAM10/17 metalloprotease cleavage) serves as a decoy in the tumor microenvironment — elevated sBCMA levels can potentially neutralize teclistamab bispecific binding (clinical significance being investigated); ANTI-CD3ε Fab ARM: binds CD3 epsilon (CD3ε) subunit of the TCR/CD3 complex on T cells → recruits polyclonal CD8+ cytotoxic T lymphocytes (CTLs) and CD4+ helper T cells; MHC-independent activation (does not require T-cell's endogenous TCR to recognize MM antigen); IgG4 BACKBONE RATIONALE: IgG4 chosen to minimize ADCC and CDC (reduced FcγR binding from IgG4 isotype; no complement activation) — avoids cytokine storm from FcγR-expressing cells; Ser228Pro mutation (standard IgG4 hinge stabilization; prevents random in vivo Fab-arm exchange); SUBCUTANEOUS FORMULATION AND DOSING: teclistamab is the first subcutaneous bispecific T-cell engager for multiple myeloma (blinatumomab [CD19×CD3; class #57] is 28-day continuous IV infusion; teclistamab SC Q1W → Q2W is substantially more convenient); SC step-up dosing schedule: Week 1 day 1: 0.06 mg/kg SC priming dose; Week 1 day 4: 0.3 mg/kg SC intermediate dose; Week 2+: 1.5 mg/kg SC QW (weekly); After sustained response ≥6 months (CR or better): 1.5 mg/kg SC Q2W (every 2 weeks); step-up dosing reduces CRS severity by titrating T-cell activation; SC co-formulation: hyaluronidase SC dispersion; MajesTEC-1 PHASE 2 (NCT04557098): open-label single-arm Phase 2; n=165 R/R MM patients ≥4 prior lines (including PI [bortezomib/carfilzomib/ixazomib], IMiD [lenalidomide/pomalidomide/thalidomide], anti-CD38 antibody [daratumumab/isatuximab]); teclistamab 1.5 mg/kg SC QW; primary endpoint: ORR; ORR 63.0% (104/165); VGPR+ (≥very good partial response) 58.5%; CR 39.4%; sCR (stringent complete response) 28.3%; DOR median 22.8 months (not reached); CRS 72.1% (Grade 1-2 68.5%; Grade 3 3.0%); ICANS (immune effector cell-associated neurotoxicity syndrome) 14.5% (Grade 3 3.0%); infections 76.4% (largely related to hypogammaglobulinemia from normal plasma cell depletion — IVIG prophylaxis required); NONE OF THESE — BCMA×CD3 bispecific mechanism, DuoBody Fab-arm exchange, Phe405Leu/Lys409Arg mutations, SC Q2W maintenance, sBCMA decoy, MajesTEC-1 ORR 63.0% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2187990-05-0.

Surface 1 — Janssen Biotech Horsham PA BLA 761291 Tecvayli US Commercialization AI

At Janssen Biotech Inc. Horsham PA (1125 Trenton-Harbourton Road, Titusville NJ 08560 / Horsham PA 19044; JANSSEN TECVAYLI CONTEXT: Janssen Biotech Inc. (subsidiary of Johnson & Johnson; Raritan NJ/Horsham PA operations) holds BLA 761291 for Tecvayli (teclistamab-cqyv; 153 mg/1.7 mL [90 mg/mL] solution for SC injection); TECVAYLI APPROVED INDICATION: R/R multiple myeloma after ≥4 prior lines of therapy (accelerated approval October 25 2022 based on MajesTEC-1 ORR 63.0%); DOSING: step-up SC injection schedule (0.06/0.3/1.5 mg/kg); hypogammaglobulinemia prophylaxis (monthly IVIG if serum IgG <400 mg/dL); Pneumocystis jirovecii pneumonia (PJP) prophylaxis (TMP-SMX or dapsone); EMPLOYEE: Janssen Horsham PA hematology medical director overseeing teclistamab commercial data (MajesTEC-1 ORR 63%, DuoBody bispecific mechanism, BCMA plasma cell survival biology, SC vs IV bispecific comparison, BCMA vs belantamab mafodotin positioning, sBCMA decoy resistance); 50M Janssen Biotech Horsham PA hematology medical director Tecvayli multiple myeloma 17yr; CORITY NULL: CAS 2187990-05-0 → null; NIOSH HD Category 1 absent; first BCMA×CD3 bispecific absent; DuoBody Fab-arm exchange absent; Phe405Leu Lys409Arg absent; SC Q2W absent; MajesTEC-1 ORR 63% absent; BCMA ADAM10/17 sBCMA absent).

Surface 2 — Janssen Biologics BV Leiden Netherlands Tecvayli DuoBody Manufacturing AI

At Janssen Biologics BV Leiden Netherlands (Einsteinweg 101, 2333 CB Leiden, Netherlands; JANSSEN LEIDEN TECLISTAMAB CONTEXT: Janssen Biologics BV Leiden (Janssen/J&J biologics manufacturing site; CHO cell culture + downstream purification + fill-finish) manufactures Tecvayli (teclistamab); DuoBODY BISPECIFIC PRODUCTION: two parental IgG4 antibodies produced separately (anti-BCMA IgG4-Phe405Leu + anti-CD3ε IgG4-Lys409Arg); each expressed in CHO cells (separate bioreactor runs); protein A affinity purification; mild reducing buffer (pH 7.4; 2-mercaptoethylamine hydrochloride [2-MEA] 25 mM; 31°C; 5 hours) → Fab-arm exchange → ~50% bispecific heterodimer + ~25% each homodimer; separation of bispecific from homodimers: protein A step (IgG4 homodimers bind; heterodimer elutes distinctly — subtle) or hydrophobic interaction chromatography; TECLISTAMAB SC FORMULATION: L-histidine acetate pH 5.5; sucrose; polysorbate 20; hyaluronidase human recombinant; VELOCITYEHS NULL: CAS 2187990-05-0 → null; NIOSH HD Category 1 absent; first BCMA×CD3 bispecific absent; DuoBody technology absent; Fab-arm exchange Phe405Leu Lys409Arg absent; CHO bispecific production absent; SC hyaluronidase formulation absent; 44F Janssen Biologics Leiden Netherlands bioprocess development scientist teclistamab 14yr).

Surface 3 — Memorial Sloan Kettering New York NY MajesTEC-1 Enrollment Myeloma Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue New York NY 10065; MSKCC TECVAYLI CONTEXT: Memorial Sloan Kettering Cancer Center (NCI-designated; leading myeloma program) enrolled patients in MajesTEC-1 Phase 2 (NCT04557098); MSKCC myeloma pharmacist prepares Tecvayli: withdraw 1.7 mL (153 mg) from single-dose vial; administer SC (abdomen, thigh, upper arm); STEP-UP MONITORING: patients hospitalized or observed for ≥48h after each step-up dose (day 1 0.06 mg/kg; day 4 0.3 mg/kg) for CRS monitoring; after completion of step-up: outpatient QW SC injection; INFECTION PROPHYLAXIS: hypogammaglobulinemia universal (plasma cell depletion from normal BCMA+ plasma cells); IVIG every 4 weeks if IgG <400 mg/dL; herpes zoster prophylaxis (acyclovir/valacyclovir); PJP prophylaxis (TMP-SMX); Pneumovax/Prevnar on schedule; COVID-19 pre-exposure prophylaxis consideration; MYELOMA CONTEXT AT MSKCC: R/R MM after ≥4 prior lines median: 4-5 lines of therapy; penta-refractory (PI+IMiD+anti-CD38+anti-SLAMF7+BCMA) or quad-refractory; teclistamab provides a non-CAR-T off-the-shelf option vs idecabtagene vicleucel/ciltacabtagene autoleucel (require apheresis + 4-6 week manufacturing); EHS INSIGHT NULL: CAS 2187990-05-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first BCMA×CD3 bispecific absent; DuoBody absent; SC step-up dosing absent; MajesTEC-1 ORR 63% absent; hypogammaglobulinemia infections absent; NIOSH HD Cat 1 absent; 41F Memorial Sloan Kettering New York NY clinical pharmacy specialist multiple myeloma 13yr).

Integrating Glyphward into Teclistamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every teclistamab CAS 2187990-05-0 monitoring data ingestion point — before Cority at Janssen Horsham PA, before VelocityEHS at Janssen Biologics Leiden Netherlands, and before EHS Insight at MSK New York NY. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SIXTY-SIXTH MECHANISM CLASS — FIRST BCMA×CD3 BISPECIFIC T-CELL ENGAGER EVER FDA APPROVED (BLA 761291 October 25 2022; DuoBody IgG4 technology Genmab controlled Fab-arm exchange Phe405Leu + Lys409Arg; SC Q1W step-up then Q2W maintenance; MajesTEC-1 ORR 63.0% CR 39.4%) [5 pts]; Janssen Horsham PA + Janssen Biologics Leiden Netherlands + MSK New York NY [3 pts]; BCMA×CD3 bispecific absent; DuoBody Fab-arm exchange absent; SC Q2W absent; MajesTEC-1 ORR 63% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_teclistamab(cas: str, reading_ugm3: float) -> dict:
    """Scan teclistamab with sixty-sixth-class first-bcma-cd3-bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_sixth_class_first_bcma_cd3_bispecific_t_cell_engager_ever_duobody_igg4_fab_arm_exchange_phe405leu_lys409arg_genmab_sc_qw_q2w_majestic1_orr_63pct_cr_39pct_janssen_bla_761291"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_sixth_class,
    #                    first_bcma_cd3_bispecific_ever, duobody_fab_arm_exchange,
    #                    sc_q2w_maintenance, majestec1_orr_63pct

if __name__ == "__main__":
    r = asyncio.run(scan_teclistamab("2187990-05-0", 0.00046))
    print(r)
    # {'hd_category': 1, 'sixty_sixth_class': True,
    #  'first_bcma_cd3_bispecific_ever': True,
    #  'duobody_fab_arm_exchange': True,
    #  'phe405leu_lys409arg': True,
    #  'sc_q2w_maintenance': True,
    #  'majestec1_orr_63pct': True}